Sucampo Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mizuho Securities Reiterates Buy on Sucampo Pharma (SCMP) as Amitiza Royalies Drives 2Q Beat
August 3, 2016 9:12 AM EDTMizuho Securities reiterated a Buy rating and $14.00 price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) following the company's 2Q earnings report. SCMP reported revenues of $52.0M and $0.23 in EPS vs. consensus of $48.6M and $0.22. The beat was driven primarily by higher royalty revenue from Amitiza... More
Sucampo Pharma (SCMP) Tops Q2 EPS by 1c
August 3, 2016 8:09 AM EDTSucampo Pharma (NASDAQ: SCMP) reported Q2 EPS of $0.23, $0.01 better than the analyst estimate of $0.22. Revenue for the quarter came in at $52 million versus the consensus estimate of $48.61 million.
For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.
... More